---
title: "Experimental cell therapy shows early promise against deadly childhood brain cancer"
description: "An early-stage trial of a genetically engineered immune therapy has shrunk tumors and extended survival in some children with diffuse midline glioma, one of the most lethal childhood cancers. Researchers stress the study is small and preliminary, and not a cure."
category: "Science"
category_url: https://newsparlor.com/category/science
author: "Jasmine Howard"
published: 2026-07-14T22:34:00.000Z
updated: 2026-07-14T22:34:00.000Z
canonical: https://newsparlor.com/article/car-t-therapy-childhood-brain-cancer-trial
tags: ["cancer", "immunotherapy", "car-t", "childrens-health", "clinical-trial"]
---
# Experimental cell therapy shows early promise against deadly childhood brain cancer

An early-stage trial of a genetically engineered immune therapy has shrunk tumors and extended survival in some children with diffuse midline glioma, one of the most lethal childhood cancers. Researchers stress the study is small and preliminary, and not a cure.

An experimental immune therapy has shown early signs of fighting one of the deadliest childhood cancers, shrinking tumors and prolonging survival in some young patients in a small clinical trial, researchers say, though they caution that the findings are preliminary.

The treatment, a form of CAR-T cell therapy, targets diffuse midline gliomas, aggressive tumors of the brain and spinal cord that are almost always fatal and for which there has long been no effective treatment. The work, carried out by a team at Stanford, was highlighted in a recent report by [Scientific American](https://www.scientificamerican.com/article/experimental-immune-therapy-shows-promise-against-deadly-childhood-brain-cancer/).

## How it works

CAR-T therapy involves removing a patient's own T cells, a type of immune cell, and genetically engineering them in the laboratory to recognize a target on cancer cells, before growing them in large numbers and returning them to the body. In this case, the cells were designed to home in on a molecule called GD2, which these tumors produce in large amounts, [according to Stanford Medicine](https://med.stanford.edu/news/all-news/2024/11/car-t-brain-cancer.html).

In the trial, of the 11 children and young adults treated, most showed some clinical benefit, several had substantial tumor shrinkage, and one patient's tumor disappeared and had not returned more than four years later. The median survival among those treated was longer than the roughly one year typically expected with the disease.

## Important caveats

Researchers were careful not to overstate the results. As an early-phase study designed mainly to test safety and dosing, it involved only a handful of patients, and the findings cannot yet be generalized. The therapy also carried serious side effects, including a dangerous inflammatory reaction known as cytokine release syndrome and temporary neurological problems; one patient died from complications at the highest dose tested, after which a lower dose was adopted.

The US Food and Drug Administration has granted the therapy a designation intended to speed the development of promising treatments, [the National Cancer Institute has noted](https://www.cancer.gov/news-events/cancer-currents-blog/2025/car-t-cell-therapy-gd2-diffuse-midline-gliomas), and larger trials are under way to test whether the early results hold up.

## Why it matters

Diffuse midline gliomas, which include a brainstem tumor known as DIPG, are diagnosed in only a few hundred children a year but are among the most feared of childhood cancers because so little can be done. Any therapy that produces meaningful tumor regressions marks a notable step, even at an early stage. The researchers describe the results as encouraging while emphasizing that much more work is needed before the approach could become a standard treatment, and that it is not yet a cure.